Browsing by author "Al-Lazikani, Bissan"
Now showing items 1-20 of 33
-
A comprehensive map of molecular drug targets.
Santos, R; Ursu, O; Gaulton, A; Bento, AP; Donadi, RS; et al. (NATURE PUBLISHING GROUP, 2017-01-01)The success of mechanism-based drug discovery depends on the definition of the drug target. This definition becomes even more important as we try to link drug response to genetic variation, understand stratified clinical ... -
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
George, SL; Izquierdo, E; Campbell, J; Koutroumanidou, E; Proszek, P; et al. (ELSEVIER SCI LTD, 2019-11-01)BACKGROUND: For children with cancer, the clinical integration of precision medicine to enable predictive biomarker-based therapeutic stratification is urgently needed. METHODS: We have developed a hybrid-capture next-generation ... -
canSAR: an integrated cancer public translational research and drug discovery resource.
Halling-Brown, MD; Bulusu, KC; Patel, M; Tym, JE; Al-Lazikani, B (OXFORD UNIV PRESS, 2012-01-01)canSAR is a fully integrated cancer research and drug discovery resource developed to utilize the growing publicly available biological annotation, chemical screening, RNA interference screening, expression, amplification ... -
canSAR: an updated cancer research and drug discovery knowledgebase.
Tym, JE; Mitsopoulos, C; Coker, EA; Razaz, P; Schierz, AC; et al. (OXFORD UNIV PRESS, 2016-01-04)canSAR (http://cansar.icr.ac.uk) is a publicly available, multidisciplinary, cancer-focused knowledgebase developed to support cancer translational research and drug discovery. canSAR integrates genomic, protein, ... -
canSAR: update to the cancer translational research and drug discovery knowledgebase.
Mitsopoulos, C; Di Micco, P; Fernandez, EV; Dolciami, D; Holt, E; et al. (OXFORD UNIV PRESS, 2021-01-08)canSAR (http://cansar.icr.ac.uk) is the largest, public, freely available, integrative translational research and drug discovery knowledgebase for oncology. canSAR integrates vast multidisciplinary data from across genomic, ... -
canSAR: update to the cancer translational research and drug discovery knowledgebase.
Coker, EA; Mitsopoulos, C; Tym, JE; Komianou, A; Kannas, C; et al. (OXFORD UNIV PRESS, 2019-01-08)canSAR (http://cansar.icr.ac.uk) is a public, freely available, integrative translational research and drug discovery knowlegebase. canSAR informs researchers to help solve key bottlenecks in cancer translation and drug ... -
canSAR: update to the cancer translational research and drug discovery knowledgebase.
di Micco, P; Antolin, AA; Mitsopoulos, C; Villasclaras-Fernandez, E; Sanfelice, D; et al. (OXFORD UNIV PRESS, 2023-01-06)canSAR (https://cansar.ai) is the largest public cancer drug discovery and translational research knowledgebase. Now hosted in its new home at MD Anderson Cancer Center, canSAR integrates billions of experimental measurements ... -
canSAR: updated cancer research and drug discovery knowledgebase.
Bulusu, KC; Tym, JE; Coker, EA; Schierz, AC; Al-Lazikani, B (OXFORD UNIV PRESS, 2014-01-01)canSAR (http://cansar.icr.ac.uk) is a public integrative cancer-focused knowledgebase for the support of cancer translational research and drug discovery. Through the integration of biological, pharmacological, chemical, ... -
ChEMBL: a large-scale bioactivity database for drug discovery.
Gaulton, A; Bellis, LJ; Bento, AP; Chambers, J; Davies, M; et al. (OXFORD UNIV PRESS, 2012-01-01)ChEMBL is an Open Data database containing binding, functional and ADMET information for a large number of drug-like bioactive compounds. These data are manually abstracted from the primary published literature on a regular ... -
Development of a Structured Query Language and Natural Language Processing Algorithm to Identify Lung Nodules in a Cancer Centre.
Hunter, B; Reis, S; Campbell, D; Matharu, S; Ratnakumar, P; et al. (FRONTIERS MEDIA SA, 2021-11-04)Importance: The stratification of indeterminate lung nodules is a growing problem, but the burden of lung nodules on healthcare services is not well-described. Manual service evaluation and research cohort curation can be ... -
Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer.
Cato, L; Neeb, A; Sharp, A; Buzón, V; Ficarro, SB; et al. (ELIFE SCIENCES PUBLICATIONS LTD, 2017-08-10)Targeting the activation function-1 (AF-1) domain located in the N-terminus of the androgen receptor (AR) is an attractive therapeutic alternative to the current approaches to inhibit AR action in prostate cancer (PCa). ... -
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers.
Stewart, A; Coker, EA; Pölsterl, S; Georgiou, A; Minchom, AR; et al. (AMER ASSOC CANCER RESEARCH, 2019-08-01)It is increasingly appreciated that drug response to different cancers driven by the same oncogene is different and may relate to differences in rewiring of signal transduction. We aimed to study differences in dynamic ... -
Distinctive Behaviors of Druggable Proteins in Cellular Networks.
Mitsopoulos, C; Schierz, AC; Workman, P; Al-Lazikani, B (PUBLIC LIBRARY SCIENCE, 2015-12-23)The interaction environment of a protein in a cellular network is important in defining the role that the protein plays in the system as a whole, and thus its potential suitability as a drug target. Despite the importance ... -
Drug discovery in advanced prostate cancer: translating biology into therapy.
Yap, TA; Smith, AD; Ferraldeschi, R; Al-Lazikani, B; Workman, P; et al. (NATURE PUBLISHING GROUP, 2016-10-01)Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses considerable therapeutic challenges. Recent genetic and technological advances have provided insights into prostate cancer biology ... -
Evolution of kinase polypharmacology across HSP90 drug discovery.
Antolin, AA; Clarke, PA; Collins, I; Workman, P; Al-Lazikani, B (CELL PRESS, 2021-10-21)Most small molecules interact with several target proteins but this polypharmacology is seldom comprehensively investigated or explicitly exploited during drug discovery. Here, we use computational and experimental methods ... -
Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes.
Coker, EA; Stewart, A; Ozer, B; Minchom, A; Pickard, L; et al. (AMER ASSOC CANCER RESEARCH, 2022-06-01)We hypothesize that the study of acute protein perturbation in signal transduction by targeted anticancer drugs can predict drug sensitivity of these agents used as single agents and rational combination therapy. We assayed ... -
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
Paschalis, A; Welti, J; Neeb, AJ; Yuan, W; Figueiredo, I; et al. (AMER ASSOC CANCER RESEARCH, 2021-02-15)Endocrine resistance (EnR) in advanced prostate cancer is fatal. EnR can be mediated by androgen receptor (AR) splice variants, with AR splice variant 7 (AR-V7) arguably the most clinically important variant. In this study, ... -
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.
Campbell, J; Ryan, CJ; Brough, R; Bajrami, I; Pemberton, HN; et al. (CELL PRESS, 2016-03-15)One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile genetic dependencies in cancer cell lines. Here, we describe data from a series of siRNA screens that identify the kinase ... -
Leveraging Human Genetics to Guide Cancer Drug Development.
Kinnersley, B; Sud, A; Coker, EA; Tym, JE; Di Micco, P; et al. (AMER SOC CLINICAL ONCOLOGY, 2018-11-21)PURPOSE: The high attrition rate of cancer drug development programs is a barrier to realizing the promise of precision oncology. We have examined whether the genetic insights from genome-wide association studies of cancer ... -
Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome.
Al-Lazikani, B; Workman, P (FUTURE SCI LTD, 2016-09-01)